ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,683.00
-0.01%
S&P ASX All Technology
3,008.10
0.02%
Brent Oil
87.225
0.01%
US Dollar vs AUD
1.53257
-0.43%
Bitcoin
63,465.44
-1.27%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ALX Oncology Holdings Inc (ALXO)

  7. ALX Oncology Holdings Inc (ALXO) News

ALXO ALX Oncology Holdings Inc

16.22
0.00 (0.00%)
Pre Market
Last Updated: 18:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
ALX Oncology Holdings Inc ALXO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 16.22 18:00:00
Open Price Low Price High Price Close Price Previous Close
16.22
more quote information »

Recent News

Date Time Source Heading
25/4/202400:00GLOBEALX Oncology Announces Two Evorpacept Abstracts Accepted for..
10/4/202407:30GLOBEALX Oncology Reports Encouraging Clinical Data of Evorpacept..
08/3/202408:05EDGAR2Form 8-K - Current report
08/3/202408:03GLOBEALX Oncology Reports Fourth Quarter and Full Year 2023..
06/3/202408:30GLOBEALX Oncology Announces Two Evorpacept Clinical Abstracts..
17/2/202410:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202410:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202410:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202408:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202408:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202408:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202408:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:00GLOBEALX Oncology to Present at the 42nd Annual J.P. Morgan..
27/12/202308:01EDGAR2Form 8-K - Current report
14/11/202308:05GLOBEALX Oncology Reports Third Quarter 2023 Financial Results..
14/11/202308:03EDGAR2Form 8-K - Current report
02/11/202307:05GLOBEALX Oncology Announces November Investor Conference..
11/10/202307:05GLOBEALX Oncology Announces Closing of Public Offering, Including..
06/10/202321:06EDGAR2Form 8-K - Current report
06/10/202321:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/10/202323:00GLOBEALX Oncology Announces Pricing of Public Offering
05/10/202308:21EDGAR2Form 8-K - Current report
05/10/202308:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/10/202307:10GLOBEALX Oncology Announces Proposed Public Offering
04/10/202323:00EDGAR2Form 8-K - Current report
04/10/202301:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03/10/202321:00GLOBEALX Oncology Reports Positive Interim Phase 2 ASPEN-06..
03/10/202307:05GLOBEALX Oncology to Host Investor Call and Webcast on October 3,..
20/9/202322:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
11/9/202314:15EDGAR2Form EFFECT - Notice of Effectiveness
09/9/202306:25EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
07/9/202306:05EDGAR2Form 8-K - Current report
06/9/202322:00GLOBEALX Oncology Realigns Executive Leadership Team
02/9/202306:11EDGAR2Form S-3 - Registration statement under Securities Act of..
31/8/202321:00GLOBEALX Oncology Announces September Investor Conference..
26/8/202306:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/8/202306:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202306:05EDGAR2Form 8-K - Current report
11/8/202306:01GLOBEALX Oncology Reports Second Quarter 2023 Financial Results..
28/7/202306:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202306:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202306:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/7/202306:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202307:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202307:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202307:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/6/202321:00GLOBEALX Oncology Receives Orphan Drug Designation from the..
12/5/202306:01GLOBEALX Oncology Reports First Quarter 2023 Financial Results..
09/5/202321:00GLOBEALX Oncology Announces First Patient Dosed in Phase 2..

Your Recent History

NASDAQ
ALXO
ALX Oncology
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved